LU87210A1 - Nouvelle composition ophtalmologique - Google Patents

Nouvelle composition ophtalmologique Download PDF

Info

Publication number: LU87210A1
Authority: LU; Luxembourg
Prior art keywords: acid; corneal; cellulose; ophthalmological composition; days
Prior art date: 1987-05-07

Application number

LU87210A

Other languages

English (en)

French (fr)

Inventor

Pierre Braquet

Original Assignee

Scras

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-07

Filing date

1988-05-06

Publication date

1988-12-13

1988-05-06 Application filed by Scras filed Critical Scras

1988-12-13 Publication of LU87210A1 publication Critical patent/LU87210A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 18
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 22
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 13
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 13
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
229920013820 alkyl cellulose Polymers 0.000 claims description 4
229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
239000002253 acid Substances 0.000 description 15
235000014113 dietary fatty acids Nutrition 0.000 description 13
239000000194 fatty acid Substances 0.000 description 13
229930195729 fatty acid Natural products 0.000 description 13
150000004665 fatty acids Chemical class 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
210000004087 cornea Anatomy 0.000 description 10
206010011033 Corneal oedema Diseases 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
201000004778 corneal edema Diseases 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
206010029113 Neovascularisation Diseases 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229940114079 arachidonic acid Drugs 0.000 description 5
235000021342 arachidonic acid Nutrition 0.000 description 5
150000003904 phospholipids Chemical class 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
229960004488 linolenic acid Drugs 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
208000006069 Corneal Opacity Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
206010023332 keratitis Diseases 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000000034 method Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000011160 research Methods 0.000 description 3
206010055665 Corneal neovascularisation Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
201000000159 corneal neovascularization Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
241000700112 Chinchilla Species 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000764238 Isis Species 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
239000004165 Methyl ester of fatty acids Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
101710173835 Penton protein Proteins 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000013475 authorization Methods 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229940079920 digestives acid preparations Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
-1 fatty acid esters Chemical class 0.000 description 1
235000019387 fatty acid methyl ester Nutrition 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
210000003128 head Anatomy 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000018931 inflamed eyes Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
229960003502 oxybuprocaine Drugs 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000029305 taxis Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LU87210A 1987-05-07 1988-05-06 Nouvelle composition ophtalmologique LU87210A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8710780		1987-05-07
GB878710780A GB8710780D0 (en)	1987-05-07	1987-05-07	Opthalmological application of eicosapentaenoic acid

Publications (1)

Publication Number	Publication Date
LU87210A1 true LU87210A1 (fr)	1988-12-13

Family

ID=10616936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87210A LU87210A1 (fr)	1987-05-07	1988-05-06	Nouvelle composition ophtalmologique

Country Status (19)

Country	Link
US (1)	US4897421A (2)
JP (1)	JPS63297323A (2)
KR (1)	KR880013557A (2)
AU (1)	AU1567888A (2)
BE (1)	BE1001075A3 (2)
CH (1)	CH675359A5 (2)
DE (1)	DE3815581A1 (2)
DK (1)	DK250088A (2)
FR (1)	FR2614790B1 (2)
GB (2)	GB8710780D0 (2)
IN (1)	IN169811B (2)
IT (1)	IT1217446B (2)
LU (1)	LU87210A1 (2)
MY (1)	MY103079A (2)
NL (1)	NL8801125A (2)
NZ (1)	NZ224363A (2)
OA (1)	OA08843A (2)
SE (1)	SE8801710L (2)
ZA (1)	ZA882963B (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2657018A1 (fr) *	1990-01-12	1991-07-19	Merck Sharp & Dohme	Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
EP0457950B1 (fr) *	1990-05-23	1993-10-20	Societe Des Produits Nestle S.A.	Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires
GB9012651D0 (en) *	1990-06-06	1990-07-25	Efamol Holdings	Essential fatty acid treatment
US5444452A (en) *	1992-07-13	1995-08-22	Matsushita Electric Works, Ltd.	Dual frequency antenna
DE4330664A1 (de) *	1993-09-10	1995-03-16	Beiersdorf Ag	Verwendungen von Pflanzenölen
FR2722410B1 (fr) *	1994-07-15	1996-10-04	Grinda Jean Robert	Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
DE19503993A1 (de) *	1995-02-08	1996-08-14	Johann Friedrich Dr Med Desaga	Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
RU2135129C1 (ru) *	1998-11-18	1999-08-27	Ларионов Евгений Викторович	Глазные капли "корнеалон-плюс"
WO2002038149A1 (en) *	2000-11-08	2002-05-16	Santen Pharmaceutical Co., Ltd.	Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient
CN101043884A (zh) *	2004-07-01	2007-09-26	谢彭斯眼科研究公司	用于治疗眼部疾病和病症的组合物和方法
US20070265341A1 (en) *	2004-07-01	2007-11-15	The Schepens Eye Research Institute Inc.	Compositions and methods for treating eye disorders and conditions
CA2611909C (en) *	2005-07-01	2014-01-07	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Composition for treatment of corneal disease
CN101222939B (zh) *	2005-07-13	2010-11-24	参天制药株式会社	眼科用防腐组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT269345B (de) *	1965-07-20	1969-03-10	Merck & Co Inc	Verfahren zur Herstellung einer sterilen, von festen Teilchen freien Zubereitung für die Augenheilkunde
US3549747A (en) *	1968-02-20	1970-12-22	Flow Pharma Inc	Contact lens wetting solution and method of using same
GB1340517A (en) *	1969-12-01	1973-12-12	Burton Parsons Chemicals Inc	Ophthalmic solution
US4136177A (en) *	1977-01-31	1979-01-23	American Home Products Corp.	Xanthan gum therapeutic compositions
GB2020180B (en) *	1978-05-08	1982-08-25	Nelson Res & Dev	Ophthalmic compositions containingcolchicine or vinblastinr
AU527784B2 (en) *	1978-05-26	1983-03-24	Bang, Hans Olaf Dr.	Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
US4599353A (en) *	1982-05-03	1986-07-08	The Trustees Of Columbia University In The City Of New York	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
FR2548021B1 (fr) *	1983-06-29	1986-02-28	Dick P R	Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
US4616012A (en) *	1983-11-25	1986-10-07	Schering Corporation	Carboxyalkyl dipeptides as antiglaucoma agents
GB8524275D0 (en) *	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
JPS6344843A (ja) *	1986-08-13	1988-02-25	Kao Corp	油中水中油型乳化油脂組成物

1987
- 1987-05-07 GB GB878710780A patent/GB8710780D0/en active Pending
1988
- 1988-04-22 NZ NZ224363A patent/NZ224363A/xx unknown
- 1988-04-26 ZA ZA882963A patent/ZA882963B/xx unknown
- 1988-04-28 IN IN373/DEL/88A patent/IN169811B/en unknown
- 1988-04-29 NL NL8801125A patent/NL8801125A/nl not_active Application Discontinuation
- 1988-04-29 MY MYPI88000451A patent/MY103079A/en unknown
- 1988-04-29 CH CH1620/88A patent/CH675359A5/fr not_active IP Right Cessation
- 1988-04-29 FR FR888805735A patent/FR2614790B1/fr not_active Expired - Lifetime
- 1988-04-29 IT IT8820388A patent/IT1217446B/it active
- 1988-05-03 GB GB8810422A patent/GB2204239B/en not_active Expired - Lifetime
- 1988-05-03 BE BE8800497A patent/BE1001075A3/fr not_active IP Right Cessation
- 1988-05-05 SE SE8801710A patent/SE8801710L/xx not_active Application Discontinuation
- 1988-05-05 OA OA59347A patent/OA08843A/xx unknown
- 1988-05-06 DE DE3815581A patent/DE3815581A1/de not_active Withdrawn
- 1988-05-06 AU AU15678/88A patent/AU1567888A/en not_active Abandoned
- 1988-05-06 KR KR1019880005253A patent/KR880013557A/ko not_active Withdrawn
- 1988-05-06 DK DK250088A patent/DK250088A/da unknown
- 1988-05-06 LU LU87210A patent/LU87210A1/fr unknown
- 1988-05-06 US US07/190,761 patent/US4897421A/en not_active Expired - Fee Related
- 1988-05-06 JP JP63109221A patent/JPS63297323A/ja active Pending

Also Published As

Publication number	Publication date
DE3815581A1 (de)	1988-11-17
GB2204239B (en)	1990-11-28
DK250088D0 (da)	1988-05-06
FR2614790A1 (fr)	1988-11-10
NL8801125A (nl)	1988-12-01
SE8801710L (sv)	1988-11-08
US4897421A (en)	1990-01-30
SE8801710D0 (sv)	1988-05-05
IT8820388A0 (it)	1988-04-29
DK250088A (da)	1988-11-08
IN169811B (2)	1991-12-28
AU1567888A (en)	1988-11-10
KR880013557A (ko)	1988-12-21
BE1001075A3 (fr)	1989-06-27
CH675359A5 (2)	1990-09-28
IT1217446B (it)	1990-03-22
JPS63297323A (ja)	1988-12-05
GB8710780D0 (en)	1987-06-10
FR2614790B1 (fr)	1991-05-31
NZ224363A (en)	1990-03-27
MY103079A (en)	1993-04-30
OA08843A (fr)	1989-03-31
GB8810422D0 (en)	1988-06-08
GB2204239A (en)	1988-11-09
ZA882963B (en)	1988-10-28

Publication	Publication Date	Title
Fingar et al.	1993	The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy
AU616713B2 (en)	1991-11-07	Use of fatty acids against cyclosporin side effects
Kay et al.	1961	Stimulation of taurocholic acid synthesis and biliary excretion of lipids
UA64797C2 (uk)	2004-03-15	Інгібітори фарнезил білок трансферази як засіб для лікування артропатії
HU229319B1 (en)	2013-10-28	Cathartic composition
FR2653997A1 (fr)	1991-05-10	Medicaments contenant comme sunstances actives des acides carboxyliques soufres, leur preparation et leur utilisation pour lutter contre les retrovirus.
BE1001075A3 (fr)	1989-06-27	Nouvelle composition ophtalmologique.
FR2629716A1 (fr)	1989-10-13	Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
SE1350179A1 (sv)	2013-04-12	Farmaceutiska sammansättningar och behandlingsförfaranden
FR2619718A1 (fr)	1989-03-03	Nouvelles formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale
Gunas et al.	2018	Indicators cell cycle and DNA fragmentation of spleen cells in early terms after thermal burns of skin at the background of introduction 0. 9% NaCl solution
FR2962655A1 (fr)	2012-01-20	Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire
JPS6094913A (ja)	1985-05-28	タールおよび脂肪酸を含む局所用剤，パツクおよびこの局所用剤の使用方法
FR2962656A1 (fr)	2012-01-20	Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
TWI284529B (en)	2007-08-01	A composition for lowering triglyceride
US5264428A (en)	1993-11-23	Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
CH651556A5 (en)	1985-09-30	Salt of (benzylindazolyl)oxyacetic acid, process for the preparation of this salt and pharmaceutical composition containing this salt
DE69737888T2 (de)	2008-04-03	Anti-mhc klasse ii bindungsreagentien zur verwendung bei xenotransplantationen
FR2705569A1 (fr)	1994-12-02	Composition pharmaceutique à base d'une imidazolylcarbazolone destinée à l'administration rectale.
FR2987264A1 (fr)	2013-08-30	Methodes et compositions pour le traitement des metastases cancereuses
JPH0118881B2 (2)	1989-04-07
FR2663543A1 (fr)	1991-12-27	Lyophilisat de potiron doux hybride et medicaments le contenant.
JP2003321369A5 (2)	2005-05-26
FR2487675A1 (fr)	1982-02-05	Nouvelles compositions pharmaceutiques injectables a base d'une phenothiazine
JPS5843385B2 (ja)	1983-09-27	シジミの薬効成分及びその製造法